The FDA issued a warning letter to NuScience Peptides LLC for marketing unapproved injectable peptide drugs, including GLP-1/GLP-2/GLP-3 products and other peptides, on its website. The agency determined these products are unapproved new drugs under the FD&C Act. FDA warned that failure to correct the violations could lead to seizure or injunction.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.